IGF-DES Overview
Mechanism of Action
IGF-DES (Des(1-3) IGF-1) is a truncated IGF-1 analog lacking the first 3 N-terminal amino acids. This prevents binding to IGF-binding proteins, giving ~10x greater receptor binding affinity at tissue level. Its very short half-life makes it ideal for localized, site-specific injection near target tissue.
~20–30 minutes
Timing
Immediately post-workout
Injection Site
Subcutaneous near target tissue/muscle
Food
No specific requirements
Common Stacks
- BPC-157 — Localized repair
- GH secretagogues — Systemic GH + localized IGF
IGF-DES Dosing Protocol
Site-Specific Protocol
4 weeks50–100 mcg SQ post-workout
Inject near target muscle immediately after training.
Conservative
4 weeks25–50 mcg locally
Lower dose for assessment.
IGF-DES Expected Timeline
Post-injection
Localized growth factor activation
Week 1–2
Enhanced local recovery
Week 3–4
Localized tissue hypertrophy
IGF-DES Side Effects
Localized swelling
Hypoglycemia (less systemic than IGF-1 LR3)
Injection site pain
IGF-DES Research Studies
Des(1-3)IGF-I is more potent than IGF-I in stimulating protein synthesis
Ballard FJ, et al. — Int J Biochem Cell Biol (1996)
IGF-DES exhibits significantly greater protein synthesis stimulation than intact IGF-1 due to inability to bind IGFBPs.
PubMed: 8930112IGF-DES FAQ
IGF-DES or IGF-1 LR3?
IGF-DES has short half-life (~20 min) with very high local potency for site-specific effects. IGF-1 LR3 has long half-life (~20+ hr) for systemic anabolic support.
Why inject near target muscle?
Due to its extremely short half-life, IGF-DES acts primarily where injected, delivering concentrated growth factor signaling before clearance.